"I have consistently expressed my concern to the committee that I do not think requiring a reduction in price for a streamlined cost pathway is an appropriate way forward," said Medicines Australia chief executive Liz de Somer. …
'If it is necessary for me to formally dissent in the final report, I will do so'
February 1, 2024 Latest NewsBioPharmaBioPharmaDispatch ExecutiveNews of the Day
Latest Video
Georgia Forrest
New Stories
-
Taylor confirms Anne Ruston will retain health portfolio in opposition reshuffle
February 17, 2026 - - Latest News -
Minister confirms PBS listing for new cystic fibrosis therapy and funded access to other medicines
February 16, 2026 - - Latest News -
Director pay rises across ASX healthcare sector, but gender balance remains uneven
February 16, 2026 - - Latest News -
Life sciences sector unites to advance women’s leadership at landmark 2026 events
February 16, 2026 - - Latest News -
New imaging agent shows stronger detection of recurrent prostate cancer in head-to-head trial
February 16, 2026 - - Australian Biotech -
Medibank funding expansion signals momentum for Emyria’s mental health model
February 16, 2026 - - Latest News -
IMF pours cold water on fears of US pharmaceutical tariffs as pressures shift to care spending
February 16, 2026 - - Latest News